Some buy side analysts are also providing their Analysis on Government Properties Income Trust, where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 1 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
BioMarin Pharmaceutical Inc. (BMRN) will report its next earnings on Feb 21 AMC. The company reported the earnings of $-0.02/Share in the last quarter where the estimated EPS by analysts was $-0.25/share. The difference between the expected and actual EPS was $0.23/share, which represents an Earnings surprise of 92%.
Many analysts are providing their Estimated Earnings analysis for BioMarin Pharmaceutical Inc. and for the current quarter 20 analysts have projected that the stock could give an Average Earnings estimate of $-0.2/share. These analysts have also projected a Low Estimate of $-0.38/share and a High Estimate of $0.04/share.
In case of Revenue Estimates, 19 analysts have provided their consensus Average Revenue Estimates for BioMarin Pharmaceutical Inc. as 391.89 Million. According to these analysts, the Low Revenue Estimate for BioMarin Pharmaceutical Inc. is 369.5 Million and the High Revenue Estimate is 429 Million. The company had Year Ago Sales of 373.45 Million.
These analysts also forecasted Growth Estimates for the Current Quarter for BMRN to be -36.4%. They are projecting Next Quarter growth of 66.67%. For the next 5 years, BioMarin Pharmaceutical Inc. is expecting Growth of 113.96% per annum, whereas in the past 5 years the growth was 68.63% per annum.
Some buy side analysts are also providing their Analysis on BioMarin Pharmaceutical Inc., where 4 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 3 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for BioMarin Pharmaceutical Inc. might touch $165 high while the Average Price Target and Low price Target is $119.86 and $81 respectively.
BioMarin Pharmaceutical Inc. closed its last trading session at $90.78 with the loss of -3.01%. The Market Capitalization of the company stands at 15.7 Billion. The Company has 52-week high of $106.74 and 52-week low of $75.81. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -4.57% where SMA50 and SMA200 are -6.01% and -8.18% respectively. The Company Touched its 52-Week High on 10/17/18 and 52-Week Low on 04/06/18.
The Relative Volume of the company is 1.03 and Average Volume (3 months) is 957.34 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 289.64.
The company shows its Return on Assets (ROA) value of -1.7%. The Return on Equity (ROE) value stands at -2.7%. While it’s Return on Investment (ROI) value is -1.5%.
While looking at the Stock’s Performance, BioMarin Pharmaceutical Inc. currently shows a Weekly Performance of -6.85%, where Monthly Performance is -0.86%, Quarterly performance is 2.53%, 6 Months performance is -11.75% and yearly performance percentage is 2.3%. Year to Date performance value (YTD perf) value is 3.41%. The Stock currently has a Weekly Volatility of 2.63% and Monthly Volatility of 2.85%.